Iq Eq Fund Management (Ireland) LTD Corbus Pharmaceuticals Holdings, Inc. Transaction History

Iq Eq Fund Management (Ireland) LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	BUY	$0.21 - $0.53 $4,604 - $11,619	21,924 Added 5.04%	457,209 $115,000
Q1 2022 Apr 28, 2022	BUY	$0.32 - $0.67 $37,317 - $78,133	116,617 Added 36.6%	435,285 $231,000
Q4 2021 Feb 02, 2022	BUY	$0.6 - $1.11 $17,424 - $32,235	29,041 Added 10.03%	318,668 $196,000
Q3 2021 Oct 27, 2021	SELL	$1.01 - $1.82 $2.62 Million - $4.72 Million	-2,594,624 Reduced 89.96%	289,627 $295,000
Q2 2021 Jul 19, 2021	BUY	$1.39 - $2.21 $1 Million - $1.6 Million	722,222 Added 33.4%	2,884,251 $5.28 Million
Q1 2021 May 11, 2021	BUY	$1.27 - $3.42 $2.67 Million - $7.2 Million	2,105,097 Added 3697.56%	2,162,029 $4.26 Million
Q4 2020 Jan 29, 2021	BUY	$0.94 - $1.89 $30,119 - $60,559	32,042 Added 128.73%	56,932 $71,000
Q3 2020 Oct 22, 2020	BUY	$1.5 - $9.38 $12,684 - $79,317	8,456 Added 51.45%	24,890 $45,000
Q2 2020 Jul 22, 2020	BUY	$4.79 - $8.39 $26,052 - $45,633	5,439 Added 49.47%	16,434 $138,000
Q1 2020 May 05, 2020	BUY	$3.44 - $7.21 $37,822 - $79,273	10,995 New	10,995 $58,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.41B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Iq Eq Fund Management (Ireland) LTD, based on Form 13F filings with the SEC.

Stay updated on Iq Eq Fund Management (Ireland) LTD with notifications on news.